Welcome to World ADC London
The 13th Annual World ADC London returns in 2023 as Europe’s longest standing and definitive
antibody-drug conjugate event - and it’s back bigger and better than before!
With the recent approval of Astrazeneca and Daiichi Sankyo’s DESTINY-Breast04, supporting Enhertu's use in HER2-low breast cancer as a new therapeutically targetable category, the ADC space has continued to make major waves throughout 2022, a joy to see for oncology patients around the world.
With high hopes set on ImmunoGen or Byondis for the next approval, you simply can’t miss out on this highly anticipated event. Exploring all aspects of ADC development from discovery to late-stage manufacturing, this is your one-stop-shop for antibody drug conjugate content.
No ADC stone is left unturned as we unite all leading players in the field under one roof. Wherever your interest and expertise lies, we have it covered at the industry's leading conference to help forward-thinking researchers from the pharmaceutical, biotech, and academic community advance the development of antibody-drug conjugates.
With more speakers, content, and networking opportunities than ever before, this is set to be the best version of the event yet and you cannot afford to miss it!
2023 Agenda will be Released Soon - Sign Up for Updates
About World ADC Series
The World ADC team ploughs its collective energy into sourcing the insights you need. We investigate the most challenging problems facing the industry; source the leading experts who have game-changing solutions; and distill this into accessible formats of information exchange – for you. From globally leading conferences, to webinars and industry reports, whatever the information you need, World ADC can offer you the insights you need to accelerate your ADC programs.
The value World ADC provides you is the power of insight and connections. Not artificial, and not short-lived. We nurture the right environments in which people can communicate problems and solutions; share novel data and forge networks across the industry that will make each of your endeavors more informed and more robust.
We share a common belief with the industry – that the potential of antibody drug conjugates is enormous. In the war against cancer, ADCs can be a game-changer and we know that the right insights and connections can sharpen the weapons that are in your arsenal.
Join us at the heart of the ADC community to improve your programmes and be part of the mission to develop better antibody drug conjugate drugs.